Dirk Wagenaar

Medical Physicist

University Medical Center Groningen
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Year:

2026

Introduction. Pseudoprogression (PsP) after proton therapy (PT) can mimic tumour progression and may cause neurological morbidity. We characterised PsP incidence, risk factors, spatial distribution and longitudinal dynamics in adults with IDH-mutated grade 2–3 glioma treated with PT.Methods. Patients treated between 2018–2022 were included. Post-PT MRIs were centrally reviewed for contrast-enhancing PsP. We estimated actuarial incidence (Kaplan–Meier), evaluated clinical risk factors using Cox regression, and analysed lesion location and volumetric behaviour over time.Results. PsP occurred in 33/137 (24.1%) patients; 8 (5.8%) developed symptomatic PsP (CTCAE grade ≥2). Mean time to first PsP was 18.1 months, and 2-year actuarial incidence was 18.1% overall (14.7% in grade 2 and 29.0% in grade 3 glioma). Independent risk factors were age >50 years (Hazard Ratio (HR) 2.5), Fazekas grade ≥2 on pre-PT MRI (HR 3.6), and treatment in 2021 (HR 3.2).In total, 115 PsP lesions were identified: 53 (46.1%) in the periventricular space (PVS) and 5 (4.3%) in the optic pathway. All symptomatic lesions involved the PVS and/or optic pathway. Symptomatic PVS-PsP showed multifocality, earlier onset (mean 14 months), faster growth (>0.5 cc/month) and larger cumulative volumes (>1.75 cc).Conclusion. Clinically consequential PsP after PT clustered in the PVS and optic pathway. Baseline clinical factors and simple volumetric dynamics may support risk-adapted surveillance and earlier multidisciplinary review, but proposed volumetric triggers require external validation.

Year:

2026

Year:

2025

Year:

2025

Background Synthetic computed tomography (sCT) images generated using deep learning (DL) methods enable the use of on‐board CBCT imaging systems for online adaptive proton therapy workflows. However, DL models are susceptible to data drifts, such as changes in the quality of the CBCT images due to software upgrades. Purpose This study aims to assess the effectiveness of transfer learning strategies in addressing changes in the input image quality and to evaluate the sustainability of potential sCT‐dependent workflows following CBCT software upgrades. Method Transfer learning strategies were utilized to re‐train two existing DL‐based sCT models (DCNN and cycleGAN). A dataset comprised 69 head and neck (HNC) patients with paired CBCT‐CT images acquired after an image reconstruction software upgrade were used for this study. 60 patients were used for training and validation, and the remaining 9 were reserved for testing. To assess the efficacy of transfer learning strategies, several transfer learning models (TL‐models) were trained using various subsets of data, ranging from 5 to 40 image pairs. Additionally, a post‐upgrade sCT (New(PU)) model was trained utilizing the complete set of 60 patients to benchmark the TL‐models to a post‐upgrade‐trained model. The synthetic CTs generated from the test set were evaluated using established image quality metrics. Furthermore, dosimetric accuracy was assessed using the patient's clinical treatment plan and our existing clinical NTCP models. Results Comparison of the average mean absolute error (MAE) between the baseline pre‐ and post‐upgrade (PU) models shows no significant difference. The baseline model exhibited an average MAE of 81.46 ± 49.0 HU and 86.25 ± 14.49 HU for DCNN and cycleGAN, respectively. The TL‐05 model demonstrated an average MAE of 69.85 ± 5.9 HU and 95.0 ± 10.95 HU, while the post‐upgrade new model had an average MAE of 74.4 ± 12.42 HU and 65.32 ± 10.36 HU for DCNN and cycleGAN, respectively. Additionally, dosimetric quantities showed no significant differences, with mean dose differences ranging from −0.98 ± 3.74% to 2.99 ± 4.74% for DCNN and −0.34 ± 5.45% to 3.15 ± 6.68% for cycleGAN, compared to the post‐upgrade new model. Evaluation of the difference between the normal tissue complication probability (∆NTCP) values between the verification CT (rCT) and post‐upgrade models showed minimal deviations ranging from −0.001% to −0.03% and 0.0006% to 0.0027% for Grade 2 or higher dysphagia, for DCNN and cycleGAN, respectively. Conclusion Transfer learning strategies, including fine‐tuning or freezing feature extraction layers, can minimize disruptions in sCT‐dependent workflows. Moreover, the small number of patients required to implement these methods can mitigate extensive downtime due to the limited availability of new data from post‐upgrade sources.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (12)

Rob J.M. Groen

Professor in Clinical Neurosurgery

University Medical Center Groningen

NETHERLANDS
View details

Roland Chiu

Scientific Staff, Other Scientific Education Staff, Docent

University of Groningen

NETHERLANDS
View details

Semi Harrabi

University Hospital Heidelberg

GERMANY
View details

Dik C. van Gent

Associate professor

Erasmus University Rotterdam

NETHERLANDS
View details

John H. Maduro

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Linh Tran

University of Wollongong

AUSTRALIA
View details

Lara Barazzuol

Associate Professor

University Medical Center Groningen

NETHERLANDS
View details

Johannes A. Langendijk

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Arjen van der Schaaf

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Armin Lühr

Technische Universität Dortmund

GERMANY
View details

Christian Richter

Head of Medical Radiation Physics Section

Helmholtz-Zentrum Dresden-Rossendorf

GERMANY
View details

Peter Dendooven

University of Helsinki

FINLAND
View details